MannKind Corporation (MNKD)

4,9950 -0,0950 (-1,87 %) À partir de 02:20PM EDT. Marché ouvert.

MannKind Corporation

1 Casper Street
Danbury, CT 06810
United States
818 661 5000
https://www.mannkindcorp.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 411

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Michael E. Castagna Pharm.D.	CEO & Director	1,53M	S.O.	1977
Ms. Lauren M. Sabella	Chief Operating Officer	1,39M	S.O.	1961
Dr. David B. Thomson J.D., Ph.D.	Executive VP, General Counsel & Secretary	862,23k	S.O.	1967
Dr. Stuart A. Tross Ph.D.	Executive VP and Chief People & Workplace Officer	739,45k	S.O.	1967
Mr. Steven B. Binder	Executive Vice President of Special Projects	854,28k	S.O.	1963
Mr. Christopher B. Prentiss M.B.A.	Chief Financial Officer	S.O.	S.O.	1975
Mr. Sanjay Singh M.B.A.	Executive Vice President of Technical Operations	364,53k	S.O.	1966
Ms. Rosabel Realica Alinaya	VP of Investor Relations & Treasury	402,26k	S.O.	1961
Mr. John F. Bedard	Senior Vice President of Worldwide Regulatory Affairs	S.O.	S.O.	1950
Mr. James Patrick McCauley Jr., J.D., M.B.A.	Chief Commercial Officer	614,06k	S.O.	1966

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Gouvernance d’entreprise

L’ISS Governance QualityScore de MannKind Corporation en date du 1 juillet 2024 est 3. Les scores principaux sont Audit : 7; Société : 2; Droits des actionnaires : 4; Compensation : 4.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.